F2RL3 and coronary artery disorder: Taken together, our intensive investigation suggested that the methylation of F2RL3 in blood could hardly be influenced by most of the environmental factors and common medical treatment, and thus, it might be a robust and stable biomarker for the baseline initial diagnosis of CHD.